Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: The referring physician's perspective

Journal of Nuclear Medicine

Volumn 56, Issue 1, 2015, Pages 70-75

  Herrmann, Ken ^a,b   Czernin, Johannes ^a   Wolin, Edward M ^c   Gupta, Pawan ^a   Barrio, Martin ^a   Gutierrez, Antonio ^a   Schiepers, Christiaan ^a   Mosessian, Sherly ^a   Phelps, Michael E ^a   Allen Auerbach, Martin S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

DOTATATE; NET; Neuroendocrine tumors; PET; Somatostatin receptor

Indexed keywords

ANTINEOPLASTIC AGENT; DOTA OCTREOTIDE GA 68; OCTREOTIDE; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; 68GA-DOTATATE; ORGANOMETALLIC COMPOUND;

ADULT; AGED; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ASSESSMENT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISTANT METASTASIS; FEMALE; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTASIS POTENTIAL; NEUROENDOCRINE TUMOR; PATIENT REFERRAL; PATIENT SAFETY; PEPTIDE RECEPTOR RADIOTHERAPY; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; QUESTIONNAIRE; REVIEW; TUMOR LOCALIZATION; VERY ELDERLY; WATCHFUL WAITING; COMPUTER ASSISTED DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; MIDDLE AGED; MULTIMODAL IMAGING; NEUROENDOCRINE TUMORS; PATHOLOGY; PHYSICIAN; RADIOGRAPHY; RESEARCH; SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM METASTASIS; NEUROENDOCRINE TUMORS; ORGANOMETALLIC COMPOUNDS; PHYSICIANS; POSITRON-EMISSION TOMOGRAPHY; QUESTIONNAIRES; REFERRAL AND CONSULTATION; RESEARCH REPORT; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84920461678     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.114.148247     Document Type: Review

References (19)

1. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States. J Clin Oncol. 2008; 26: 3063-3072.
2. Fischer L, Bergmann F, Schimmack S, et al. Outcome of surgery for pancreatic neuroendocrine neoplasms. Br J Surg. 2014; 101: 1405-1412.
3. Sharma P, Arora S, Dhull VS, et al. Evaluation of Ga-DOTANOC PET/CT imaging in a large exclusive population of pancreatic neuroendocrine tumors. Abdom Imaging. August 19, 2014 [Epub ahead of print].
4. Boninsegna L, Panzuto F, Partelli S, et al. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections. Eur J Cancer. 2012; 48: 1608-1615.
5. Welin S, Stridsberg M, Cunningham J, et al. Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinology. 2009; 89: 302-307.
6. de Herder WW, Hofland LJ, van der Lely AJ, Lamberts SW. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocr Relat Cancer. 2003; 10: 451-458.
7. Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology. 2005; 128: 1717-1751.
8. Sundin A. Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol. 2012; 26: 803-818.
9. Maecke HR, Reubi JC. Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment. J Nucl Med. 2011; 52: 841-844.
10. Werner RA, Bluemel C, Allen-Auerbach MS, Higuchi T, Herrmann K. Galliumand yttrium-/lutetium: "theranostic twins" for diagnosis and treatment of NETs. Ann Nucl Med. August 20, 2014 [Epub ahead of print].
11. 111In-DTPA-octreotide scintigraphy. J Nucl Med. 2010; 51: 875-882.
12. 68Ga-DOTATATE as measured by PET/CT in patients with neuroendocrine tumors. J Nucl Med. 2011; 52: 1679-1683.
13. 68Ga. Eur J Nucl Med Mol Imaging. 2005; 32: 478-485.
14. Halpern BS, Dahlbom M, Quon A, et al. Impact of patient weight and emission scan duration on PET/CT image quality and lesion detectability. J Nucl Med. 2004; 45: 797-801.
15. Kinahan PE, Townsend DW, Beyer T, Sashin D. Attenuation correction for a combined 3D PET/CT scanner. Med Phys. 1998; 25: 2046-2053.
16. 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg. 2010; 252: 850-856.
17. Hofman MS, Kong G, Neels OC, Eu P, Hong E, Hicks RJ. High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. J Med Imaging Radiat Oncol. 2012; 56: 40-47.
18. 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors. Neuroendocrinology. 2010; 91: 101-109.
19. 18F-FDG PET. J Nucl Med. 2010; 51: 704-712.